{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T14:49:40Z","timestamp":1785682180978,"version":"3.56.0"},"reference-count":26,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2018,1,15]]},"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.<\/jats:p>","DOI":"10.1136\/jclinpath-2017-204943","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T12:38:31Z","timestamp":1518093511000},"page":"388-394","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee"],"prefix":"10.1136","volume":"71","author":[{"given":"Newton A C S","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Cellular Pathology, Southmead Hospital, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Amary","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital, Stanmore, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Butler","sequence":"additional","affiliation":[{"name":"All Wales Genetics Laboratory, University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Byers","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Central Manchester University Hospitals NHS Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Centre for Cancer Research and Cell Biology, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R","family":"Haynes","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, University of Bristol and Southmead Hospital, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ilyas","sequence":"additional","affiliation":[{"name":"Division of Cancer and Stem Cells and Nottingham Molecular Pathology Node, Queen\u2019s Medical Centre, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Salto-Tellez","sequence":"additional","affiliation":[{"name":"Northern Ireland - Molecular Pathology Laboratory, Queen\u2019s University, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Taniere","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"2025092510163414000_71.5.388.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2025092510163414000_71.5.388.2","unstructured":"NICE. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. 2010 https:\/\/www.nice.org.uk\/guidance\/ta208."},{"key":"2025092510163414000_71.5.388.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-010-0952-2"},{"key":"2025092510163414000_71.5.388.4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.198"},{"key":"2025092510163414000_71.5.388.5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025092510163414000_71.5.388.6","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202467"},{"key":"2025092510163414000_71.5.388.7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0028"},{"key":"2025092510163414000_71.5.388.8","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/PAS.0000000000000598","article-title":"Barrett\u2019s Esophagus: A Comprehensive and Contemporary Review for Pathologists","volume":"40","author":"Naini","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2025092510163414000_71.5.388.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2011.04017.x"},{"key":"2025092510163414000_71.5.388.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142466","article-title":"High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients","volume":"10","author":"Tan","year":"2015","journal-title":"PLoS One"},{"key":"2025092510163414000_71.5.388.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2010.03711.x"},{"key":"2025092510163414000_71.5.388.12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10120-013-0329-8","article-title":"Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization","volume":"17","author":"Yamashita-Kashima","year":"2014","journal-title":"Gastric Cancer"},{"key":"2025092510163414000_71.5.388.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2010.08.012"},{"key":"2025092510163414000_71.5.388.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8197"},{"key":"2025092510163414000_71.5.388.15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cncy.21692","article-title":"Validation of immunocytochemistry as a morphomolecular technique","volume":"124","author":"Maxwell","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"2025092510163414000_71.5.388.16","unstructured":"EMA. Herceptin -EMEA\/H\/C\/000278 -IB\/129. 2017; http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000278\/human_med_000818.jsp&mid=WC0b01ac058001d124."},{"key":"2025092510163414000_71.5.388.17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00428-014-1597-3","article-title":"Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma","volume":"465","author":"Yoshida","year":"2014","journal-title":"Virchows Arch"},{"key":"2025092510163414000_71.5.388.18","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202571"},{"key":"2025092510163414000_71.5.388.19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2559.2012.04272.x","article-title":"Early HER2 dysregulation in gastric and oesophageal carcinogenesis","volume":"61","author":"Fassan","year":"2012","journal-title":"Histopathology"},{"key":"2025092510163414000_71.5.388.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.9984"},{"key":"2025092510163414000_71.5.388.21","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202404"},{"key":"2025092510163414000_71.5.388.22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10120-015-0518-8","article-title":"Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)","volume":"19","author":"Matsusaka","year":"2016","journal-title":"Gastric Cancer"},{"key":"2025092510163414000_71.5.388.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-014-0402-y"},{"key":"2025092510163414000_71.5.388.24","doi-asserted-by":"crossref","unstructured":"Kim WH , Gomez-Izquierdo L , Vilardell F , et al . HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. Appl Immunohistochem Mol Morphol 2016. doi:10.1097\/PAI.0000000000000423. [Epub ahead of print 3 Aug 2016].doi:10.1097\/PAI.0000000000000423","DOI":"10.1097\/PAI.0000000000000423"},{"key":"2025092510163414000_71.5.388.25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10120-014-0430-7","article-title":"Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer","volume":"18","author":"Kurokawa","year":"2015","journal-title":"Gastric Cancer"},{"key":"2025092510163414000_71.5.388.26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.5858\/2011-0084-ED.1","article-title":"Where and by whom should gastric cancer HER2\/neu status be assessed?: lessons from breast cancer","volume":"135","author":"Salto-Tellez","year":"2011","journal-title":"Arch Pathol Lab Med"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2017-204943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:16:45Z","timestamp":1758820605000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2017-204943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,18]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/jclinpath-2017-204943"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2017-204943","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]}}}